Clinical trials
Systemic Sclerosis (SSc) clinical trials
Below are recruiting systemic sclerosis (ssc) clinical trials, each written for real people, not researchers. We’re tracking 103 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07245238RecruitingPhase 3
CBD lotion for itching in scleroderma
This trial tests if a CBD (cannabidiol) lotion can help reduce itching in people with scleroderma, a condition that often causes chronic itch. It compares the CBD lotion to a placebo (inactive lotion) to see if it works and is safe.
Khon KaenAges 18–70 - NCT07491523Recruiting
Adding anti-fibrotic to immunosuppression for scleroderma lung disease
This trial is testing whether adding an anti-fibrotic drug (a medicine that fights scarring) to two immunosuppressive drugs works better than the two drugs alone for people with scleroderma-related lung disease.
PátraiAges 18 years+ - NCT06297096RecruitingPhase 3
Testing a two-drug combo for lung scarring in scleroderma
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
Warsaw, Masovian VoivodeshipAges 18–74 - NCT06549231RecruitingPhase 3
Rituximab and mycophenolate for scleroderma lung disease
This trial tests whether combining two drugs, rituximab and mycophenolate mofetil, is safe and works better than standard care for lung scarring caused by scleroderma. It may be an option if your lung disease is severe or getting worse.
ToursAges 18–100 - NCT06189495RecruitingPhase 2
Study of Genakumab for lung scarring from connective tissue disease
This study tests a new injected medication (Genakumab) for people with connective tissue disease-related lung scarring. It aims to see if it helps stabilize or improve lung function safely.
Beijing, Beijing MunicipalityAges 18–75 - NCT06472362Enrolling by invitation
Chest CT scans to predict lung disease in scleroderma
This study looks at using chest CT scans to help predict how lung disease from scleroderma (SSc-ILD) may progress. It may help doctors better understand your condition.
ParisAges 18–99 - NCT05482607Recruiting
CT scan pattern study in lung disease from systemic sclerosis
This study looks at patterns seen on a high-resolution CT (HRCT) scan to better understand lung disease that can occur with systemic sclerosis. It may help doctors recognize which lung changes go with which type of disease.
NancyAges 18 years+ - NCT06936215RecruitingPhase 3
Baricitinib vs methotrexate for skin tightening in scleroderma
This study tests if baricitinib (a daily pill) is better than methotrexate (a common treatment) at reducing skin tightening in people with a severe type of scleroderma called diffuse cutaneous systemic sclerosis. It may help if your skin is getting tighter and you have been diagnosed in the last 5 years.
DhakaAges 18 years+ - NCT05108857Enrolling by invitation
PET scan study for early active systemic sclerosis
This trial uses PET/CT scans with special tracers to look at inflammation and activity in systemic sclerosis (scleroderma) soon after symptoms begin. It may help researchers understand what’s driving active disease and where it shows up in the body.
TurkuAges 18 years+ - NCT06685042RecruitingPhase 1/Phase 2
CAR T-cell therapy for severe autoimmune diseases
This study tests a new treatment called CAR T-cell therapy for people with severe autoimmune diseases that haven't gotten better with standard treatments. The goal is to see if it can help control the disease by reprogramming your immune cells.
Rome, LazioAges 18–65 - NCT06434363RecruitingPhase 1/Phase 2
Cell therapy plus tafasitamab for autoimmune diseases
This trial tests a new cell therapy (AD-PluReceptor) combined with the drug tafasitamab for people with certain autoimmune diseases like systemic sclerosis, lupus, or chronic graft-versus-host disease. It aims to see if this treatment can help when standard therapies have failed.
Houston, TexasAges 18 years+ - NCT07345052Recruiting
Study on systemic sclerosis in western Sweden
This study is looking at people with systemic sclerosis (a condition that causes hardening and tightening of the skin and can affect internal organs) to learn more about the disease. You may join if you have been diagnosed with this condition and meet a few other requirements.
Gothenburg, SwedenAges 18 years+ - NCT06548607RecruitingEarly Phase 1
CAR-T therapy for autoimmune diseases
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
Bengbu, AnhuiAges 18–70 - NCT06347718RecruitingPhase 1/Phase 2
Car-T cells for autoimmune disease
This study tests a type of immunotherapy called CAR-T cells for people with certain autoimmune diseases like lupus, scleroderma, or myositis. It aims to see if this treatment can help when standard medicines haven't worked well enough.
Erlangen, BavariaAges 18 years+ - NCT06947473RecruitingPhase 1/Phase 2
CAR T-cell therapy for lupus, sclerosis, and Sjogren's
This trial tests a new type of immune cell therapy (CAR T-cells from umbilical cord blood) for people with certain autoimmune diseases that haven't responded to standard treatments. It aims to see if targeting two proteins (CD19 and BCMA) can help calm the overactive immune system.
Beijing, Beijing MunicipalityAges 6–65 - NCT07515638Recruiting
Immune System Study for Autoimmune Diseases
This research study collects samples and information from people with rheumatoid arthritis, lupus, or scleroderma, plus healthy volunteers, to better understand how the immune system works in these conditions. By comparing these groups, researchers hope to find new ways to treat and manage autoimmune diseases.
MontpellierAges 18 years+ - NCT07558850Recruiting
CAR-T Cell Therapy for Treatment-Resistant Autoimmune Diseases
This study tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like rheumatoid arthritis, lupus, dermatomyositis, and scleroderma that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and eliminate the B cells that are causing your autoimmune disease.
Nanjing, JiangsuAges 18–70 - NCT07361094RecruitingPhase 1
CAR-T therapy for autoimmune disease after prior treatment
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It is for people with certain autoimmune diseases (like lupus or scleroderma) that have not responded well to standard treatments or have relapsed after prior cell therapy.
BeijingAges 18–70 - NCT07038447Enrolling by invitationPhase 1
KITE-363 for refractory autoimmune diseases
This trial tests a new cell therapy called KITE-363 for people with certain autoimmune diseases (lupus, lupus nephritis, systemic sclerosis, or idiopathic inflammatory myopathy) that haven't improved with standard treatments. It aims to see if this therapy can help control the disease.
Duarte, CaliforniaAges 18 years+ - NCT06947460RecruitingPhase 1/Phase 2
CAR-T cell therapy for resistant lupus, sclerosis, and Sjögren's lung disease
This trial tests a special immune cell therapy (CAR-T cells targeting CD19 and BCMA) for people with lupus nephritis, systemic sclerosis, or Sjögren's-related lung blood vessel disease that hasn't improved with usual treatments. The goal is to see if this one-time cell infusion can calm the overactive immune system and improve symptoms.
Beijing, China,BeijingAges 10–65 - NCT07085104RecruitingPhase 1
Study of ALLO-329 for lupus, myositis, or scleroderma
This trial tests a new one-time cell therapy (ALLO-329) made from donor cells to target and calm overactive immune cells in people with lupus, myositis, or scleroderma that hasn't improved with usual medications. It aims to see if this treatment is safe and can help reduce disease activity.
Phoenix, ArizonaAges 18–74 - NCT07339540RecruitingEarly Phase 1
BCMA gene therapy for recurring autoimmune diseases
This early-phase trial tests a new gene therapy (BCMA LV injection) for people with autoimmune diseases like lupus, IgG4-related disease, scleroderma, myositis, or vasculitis that keep coming back or don't respond to standard treatments. The goal is to see if targeting a specific immune cell protein (BCMA) can help control the disease.
Wuhan, HubeiAges 18–65 - NCT06732674Recruiting
Home-based care for lung disease in rheumatic conditions
This trial tests whether people with lung disease caused by a rheumatic condition can safely manage their care at home using a smartphone or tablet. It aims to see if home monitoring is as effective as in-person visits for keeping your lungs healthy.
OsloAges 18 years+ - NCT07543679Recruiting
Measuring Skin Damage in Systemic Sclerosis with a Skin Sensor
This study tests a sensor device called ADHELASKIN to see if it can accurately measure skin damage in people with systemic sclerosis (SSc), a condition that hardens and tightens the skin. The goal is to find a better way to track skin changes during the disease.
Saint-Priest-en-Jarez, Pays de la Loire RegionAges 18 years+
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for systemic sclerosis (ssc)?
- Yes. Clin2 currently lists 103 recruiting systemic sclerosis (ssc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a systemic sclerosis (ssc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a systemic sclerosis (ssc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.